Elicio Therapeutics, Inc. ELTX
1.63 USD +0.02 (+1.24%)
At closeNov 11, 2026, 5:14 PM EST
1.60 -0.03 -1.84%
After hours · Nov 11, 5:14 PM ET
1.53 Day range 1.67
1.40 52-week range 14.85
- YTD
- -79.52%
- 1 year
- -82.34%
News
seekingalpha.com Elicio Therapeutics, Inc. (ELTX) Discusses Camupepimut Development in Neoadjuvant and Metastatic Pancreatic Cancer Transcript Elicio Therapeutics, Inc. ( ELTX ) Discusses Camupepimut Development in Neoadjuvant and Metastatic Pancreatic Cancer November 11, 2026 2:30 PM EST Company Participants Christopher Haqq - Executive…
benzinga.com HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Lowers Price Target to $21 HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $23 to $21.
benzinga.com Elicio Therapeutics Q3 EPS $(0.30) Beats $(0.43) Estimate Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.43) by 30.23 percent. This is a 50 percent increase over losses of…
globenewswire.com Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
globenewswire.com Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
benzinga.com Elicio Therapeutics To Demonstrate Data Of Two Poster Presentations For Its Phase 2 AMPLIFY-7P Trial Of Camupepimut , Expanded Antigen-Agnostic Intratumoral Application Of AMP-Adjuvant Platform At Society For Immunotherapy Of Cancer's Annual Meeting Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that…
globenewswire.com Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer Additional…
benzinga.com Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results At ESMO Congress 2026; Multiple Pre-Specified Subgroup Analyses Favored Camupepimut, Including Patients With And Without Detectable Baseline ctDNA; Encouraging Disease-Free Survival Outcomes Were Observed In Both ctDNA-Negative And ctDNA-Positive Patients Elicio Therapeutics, Inc. (NASDAQ:ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results
benzinga.com Elicio Therapeutics Presents Data From Its Phase 2 AMPLIFY-7P Trial Of Camupepimut At European Society For Medical Oncology Congress 2026 Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results
globenewswire.com Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine BOSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics…- benzinga.com B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8 B. Riley Securities analyst Mayank Mamtani maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $27 to $8.
globenewswire.com Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026 New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancer Findings are expected to inform…
globenewswire.com Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
globenewswire.com Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
benzinga.com HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $23 price target.- benzinga.com Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) Estimate Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 34.85 percent increase over losses of…
globenewswire.com Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. ("Elicio" or the "Company") (NASDAQ: ELTX). Such investors are advised…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX). Such investors are…
globenewswire.com Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
benzinga.com 11 Health Care Stocks Moving In Thursday's Intraday Session Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million. Liminatus Pharma…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 40.9% to $0.16 during Thursday's pre-market session. The market value of their outstanding shares is at $5.8 million. Stablecoin Development…
globenewswire.com Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX). Such investors are…
globenewswire.com Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
businesswire.com ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm LOS ANGELES--(BUSINESS WIRE)---- $ELTX--ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. ("Elicio" or the "Company") (NASDAQ: ELTX). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX). Such investors are…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating earnings and revenue estimates. Other gainers include LNKS, ADTX, and SPRO.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is up on Wednesday as the company reported promising clinical observations regarding its ELI-002 7P treatment.
globenewswire.com Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer 100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Crude Oil Tumbles Over 5%; Empire State Manufacturing Index Falls In June US stocks gain on peace agreement with Iran, Nasdaq up 2%, Dow up 1.1%, S&P 500 up 1.54%. Tech shares jump 2.8%, energy stocks fall 3.5%. Empire State manufacturing index drops to 5.7. Industrial…
benzinga.com Dow Jumps Over 600 Points Following US-Iran Peace Deal US stocks rise on peace agreement with Iran, Dow up 600 points. Tech sector jumps, energy stocks down. Trump announces deal, oil futures decline.- benzinga.com 10 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket 
benzinga.com Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session